Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
15 May 24
8-K
Leap Therapeutics Reports First Quarter 2024 Financial Results
13 May 24
10-Q
2024 Q1
Quarterly report
13 May 24
S-3
Shelf registration
10 May 24
EFFECT
Notice of effectiveness
10 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Leap Therapeutics Announces $40 Million Private Placement
11 Apr 24
S-3
Shelf registration
18 Mar 24
8-K
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
18 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
S-8
Registration of securities for employees
26 Jan 24
8-K
Other Events
23 Jan 24
8-K
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study
16 Jan 24
8-K
Other Events
12 Dec 23
8-K
Leap Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Other Events
13 Sep 23
S-8
Registration of securities for employees
30 Aug 23
8-K
Leap Therapeutics Reports Second Quarter 2023 Financial Results
14 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Leap Therapeutics Announces Initiation of Randomized Controlled Part B
12 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
21 Jun 23
8-K
Leap Therapeutics Announces Reverse Stock Split
20 Jun 23
EFFECT
Notice of effectiveness
15 Jun 23
424B3
Prospectus supplement
14 Jun 23
CORRESP
Correspondence with SEC
12 Jun 23
S-3/A
Shelf registration (amended)
9 Jun 23
8-K
Other Events
25 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Leap Therapeutics Reports First Quarter 2023 Financial Results
15 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
UPLOAD
Letter from SEC
27 Apr 23
8-K
Leap Therapeutics to Present Updated Data from
26 Apr 23
S-3
Shelf registration
21 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
8-K
Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of
12 Apr 23
8-K
Departure of Directors or Certain Officers
7 Apr 23
Latest ownership filings
SC 13G
Samsara BioCapital, L.P.
25 Apr 24
SC 13G
GILEAD SCIENCES, INC.
19 Apr 24
3
Initial statement of insider ownership
19 Apr 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
4
Nissim Mashiach
31 Jan 24
4
Thomas John Dietz
31 Jan 24
4
Richard Schilsky
31 Jan 24
4
Christine Granfield
31 Jan 24
4
Jason Baum
31 Jan 24
4
Christian M Richard
31 Jan 24
4
John Mark O'Mahony
31 Jan 24
4
Cynthia Sirard
31 Jan 24
4
Patricia A. Martin
31 Jan 24
4
AUGUSTINE LAWLOR
31 Jan 24
4
JOSEPH LOSCALZO
31 Jan 24
4
Christopher Mirabelli
31 Jan 24
4
DOUGLAS E ONSI
31 Jan 24
4
WILLIAM LI
31 Jan 24
4
JAMES H CAVANAUGH
31 Jan 24
4
Christopher Mirabelli
30 Jan 24
4
John Mark O'Mahony
30 Jan 24
4
Cynthia Sirard
30 Jan 24
4
AUGUSTINE LAWLOR
30 Jan 24
4
DOUGLAS E ONSI
30 Jan 24
4
Thomas John Dietz
25 Aug 23
4
WILLIAM LI
25 Aug 23
4
Patricia A. Martin
25 Aug 23
4
AUGUSTINE LAWLOR
25 Aug 23
4
Nissim Mashiach
25 Aug 23
4
Christian M Richard
25 Aug 23
4
Christopher Mirabelli
25 Aug 23
4
DOUGLAS E ONSI
25 Aug 23
4
Richard Schilsky
25 Aug 23
4
JAMES H CAVANAUGH
25 Aug 23
4
Christine Granfield
25 Aug 23
4
John Mark O'Mahony
25 Aug 23
4
Jason Baum
25 Aug 23
4
Cynthia Sirard
25 Aug 23
4
JOSEPH LOSCALZO
25 Aug 23
4
Christopher Mirabelli
4 Apr 23